Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Molecular diagnostics group Yourgene Health reported a narrower first-half loss after its revenue almost doubled.
Pre-tax losses for the six months through September amounted to £1.34m, compared to losses of £3.46m on-year.
Revenue rose 97% to £7.8m, or by 56% when excluding contributions from the acquisition of Elucigene.
The company swung to an adjusted Ebitda profit of £0.3m, its first, from a loss of £2.5m.
'I am delighted to announce our first Ebitda profit as a demonstration of the transformation that is underway at Yourgene and resultant organic growth, supported by the contribution from Elucigene and the smooth integration process that is almost complete,' chief executive Lyn Rees said.
' The reorientation of the business to focus on our key four strategic growth drivers is starting to bear fruit, and I remain convinced we have a very significant opportunity ahead of us.'
'We are confident in our outlook for the year end and very excited about the prospects for further growth over the following years.'
At 9:46am: (LON:YGEN) share price was +0.13p at 13.63p